Equities Analysts Offer Predictions for Ascendis Pharma A/S’s FY2024 Earnings (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Cantor Fitzgerald cut their FY2024 earnings estimates for shares of Ascendis Pharma A/S in a note issued to investors on Tuesday, October 1st. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will earn ($6.80) per share for the year, down from their prior estimate of ($6.54). Cantor Fitzgerald has a “Overweight” rating and a $170.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.15) per share.

A number of other research analysts have also recently weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, TD Cowen dropped their price target on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $195.00.

Ascendis Pharma A/S Stock Down 0.2 %

ASND opened at $146.29 on Thursday. The stock has a market cap of $8.52 billion, a price-to-earnings ratio of -15.22 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The company’s 50-day moving average price is $134.89 and its two-hundred day moving average price is $136.34.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of ASND. Vestal Point Capital LP bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $78,719,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $16,648,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.